CBL and neoplasm: Notably, hypoxic tumor cells with constitutive and high EGFR activation (CAL-27 and HN30 cells) appear to employ some previously unknown antagonistic mechanisms to bypass the inhibitory effect of ubiquitination-mediated degradation by blocking the binding of Cbl/Grb2 to EGFR.